Find your PDFs fast.
Welcome to the Pubget Medical Subject Headings (MESH) browser. Click on a topic or subtopic below to explore related papers. In the gold box is the most recent paper about the current MESH term, and below are 20 related papers.
Toremifene (0):
Recent article
Toremifene
Abstract
We have performed pelvic magnetic resonance imaging (MRI) in patients undergoing breast cancer surgery before and after adjuvant drug therapy. Our purpose was to detect any radiographic uterine changes induced by various types of adjuvant therapy on pre- and postmenopausal patients by evaluating pro...
|
PMID: 20661693
PDF is available here.
PDF is available here.
| < More recent | Older article > |
Abstract
Distinct differences between two selective estrogen receptor modulators on lipids were observed. Toremifene improved lipid profiles, particularly as an enhancer of high-density lipoprotein cholesterol. To a large extent, tamoxifen improved low-density lipoprotein cholesterol levels. The impact of th...
|
PMID: 20382637
PDF is available here.
PDF is available here.
Abstract
Of 194 patients with endometrial cancer, 18 (9.3%) developed breast cancer before endometrial cancer diagnosis. Mean age was 66 years, and the median time interval between breast and endometrial cancer diagnosis was 10 years (range, 1.5 -32 years). Nine patients developed aggressive tumors(serous, c...
|
PMID: 20154485
PDF is available here.
PDF is available here.
Acta Radiologica (50)9 2009
Abstract
Nine patients were evaluable for this analysis. Both the enhancement ratio and the maximum slope of enhancement tended to be smaller during the toremifene cycles as compared to placebo. On the left side, the difference in the maximum slope of enhancement between toremifene and placebo was statistica...
|
PMID: 19863407
PDF is available here.
PDF is available here.
Abstract
The complete response rate of AI therapy was 16.7% (2/12). The clinical benefit rate was 58.3% (7/12). The median of time to progression (TTP) was 33.8 weeks. Neither the presence nor absence of past history of treatment with tamoxifen (TAM) or other chemotherapies affected the anti-tumor effect. An...
|
PMID: 19755813
PDF is available here.
PDF is available here.
Acta Medica Okayama (63)4 2009
Abstract
Toremifene citrate is expected to prevent drug resistance in cancer patients by inhibiting p-glycoprotein activity. The safety and efficacy of combination therapy with high-dose toremifene citrate and paclitaxel were investigated. Between December 2003 and June 2004, 15 women with a mean age of 53 y...
|
PMID: 19727203
PDF is available here.
PDF is available here.
Fertility and Sterility (91)4 Suppl 2009
Abstract
This study evaluates, compares, and contrasts the effects of three selective estrogen receptor modulators (SERMs), namely, tamoxifen, toremifene, and raloxifene, on the hypothalamic-pituitary-testicular axis in 284 consecutive subfertile men with idiopathic oligozoospermia using three therapeutic pr...
|
PMID: 18692782
PDF is available here.
PDF is available here.
BJU International (103)7 2009
Abstract
Prostate cancer is among the most common causes of death from cancer in men, and accounts for 10% of all new male cancers worldwide. The diagnosis and treatment of prostate cancer place a substantial physical and emotional burden on patients and their families, and have considerable financial implic...
|
PMID: 19302133
PDF is available here.
PDF is available here.
Abstract
The patient was a 56-year-old female. At the age of 35 years, she had under gone left mastectomy and axillary lymph node dissection for breast cancer. After surgery, hormonal therapy was continued for 3 years. Then, no treatment was performed. In this study, single therapy with an AI agent was start...
|
PMID: 19381046
PDF is available here.
PDF is available here.
Georgian medical news ()168 2009
Abstract
We estimated cholesterol fractions, triglycerides and high and low density lipoproteins both prior to the beginning of hormonotherapy, and in 3, 6, 12 months. After 12 month of hormonotherapy with Tamoxifen 20 mg/day all fractions of very low density lipoproteins were increased. Patients treated wit...
|
PMID: 19359718
PDF is available here.
PDF is available here.
Anti-Cancer Drugs (20)1 2009
Abstract
We have established estrogen-independent and antiestrogen-resistant cell lines from hormone-dependent MCF-7 breast cancer cells by long-term culture in the absence of estrogen, or in the presence of antiestrogen toremifene, respectively. By using a cDNA microarray we compared gene expression profile...
|
PMID: 19343000
PDF is available here.
PDF is available here.
Abstract
We report a case of advanced breast cancer with skin ulceration and bleeding (T4bN3bM0: Stage IIIC) achieving a significant improvement of QOL by toremifene and paclitaxel therapy. The patient was a 38-year-old woman with slight anemia who had ulcerative breast lump with skin ulcer. A core needle bi...
|
PMID: 19106576
PDF is available here.
PDF is available here.
Abstract
We report a case of recurrence of skin and lymph nodes from asynchronous breast cancer achieving a significant improvement of QOL by toremifene and paclitaxel therapy. The patient was a 49-year-old woman who received both sides of muscle-preserving radical mastectomy (Bt+Ax: Auchincloss) had a skin...
|
PMID: 19106577
PDF is available here.
PDF is available here.
Abstract
We attempted to verify in an experimental model the role of cytoplasmic clusterin (CLU), a cytoprotective protein found to be up-regulated in antiestrogen-resistant patients, following neoadjuvant treatment with toremifene. The role of cytoplasmic clusterin in modulating response to two antiestrogen...
|
PMID: 18813793
PDF is available here.
PDF is available here.
Abstract
Abstract
Of the 1,811 patients enrolled in the NAFTA trial, 1,222 (67.4%) had BCS. Of these, 241 (19.7%) did not have RT. There were no significant differences in tumor grade, lymphovascular invasion, estrogen receptor status, or nodal status between those who received RT and those who did not. On univariate...
|
PMID: 18417083
PDF is available here.
PDF is available here.
Endocrine-Related Cancer (15)2 2008
Abstract
This study aimed to define a gene expression profile associated with response to anti-estrogen treatment in estrogen receptor alpha (ERalpha)-positive breast cancer from elderly patients and to identify possible candidate genes associated with resistance by detecting those modulated by treatment. Us...
|
PMID: 18508997
PDF is available here.
PDF is available here.
Journal of Clinical Oncology (26)11 2008
Abstract
Changes in serum lipids differed significantly between the groups. Mean (+/- SE) total cholesterol decreased by 1.0% +/- 1.7% from baseline to month 12 in the placebo group and decreased by 8.1% +/- 1.4% in the toremifene group (P = .001 for between group comparison). Low-density lipoprotein (LDL) c...
|
PMID: 18398147
PDF is available here.
PDF is available here.
Zhongguo shi yan xue ye xue za zhi / Zhongguo bing li sheng li xue hui = Journal of experimental hematology / Chinese Association of Pathophysiology (16)1 2008
Abstract
This study was aimed to investigate the reversible effect of tetrandrine, toremifene and their combination on multidrug resistance of K562/A02 cell line. The IC(50) (the concentration causing 50% inhibition of cell growth) of adriamycin (ADR) were assayed by MTT method, the expression of MDR1 mRNA w...
|
PMID: 18315901
PDF is available here.
PDF is available here.
Abstract
We discuss the capabilities of liquid chromatography coupled to mass spectrometry with a time-of flight system with accurate mass measurement for the detection and characterisation of drug metabolites in biological samples for anti-doping purpose. Urinary excretion samples of three selective oestrog...
|
PMID: 18708697
PDF is available here.
PDF is available here.
Journal of Urology (179)1 2008
Abstract
Toremifene significantly increased hip and spine bone mineral density in men receiving androgen deprivation therapy for prostate cancer. The effect of toremifene on the fracture risk is being assessed in the ongoing randomized, controlled trial....
|
PMID: 18001802
PDF is available here.
PDF is available here.
Abstract
We developed a model system that mimics this situation. In this model, tumors of human estrogen receptor (ER) positive breast cancer cells stably transfected with aromatase (Ac-1) are grown in immune-compromised mice. Using this model we have explored a number of therapeutic strategies to maximize t...
|
PMID: 17942301
PDF is available here.
PDF is available here.
Journal of Clinical Oncology (25)31 2007
Abstract
A total of 865 patients were randomly assigned (434 to ATA + TOR and 431 to LET) in 60 centers in the United States, Canada, Russia, and Ukraine. Baseline characteristics were balanced. Median TTP was identical in the two arms at 11.2 months (P < .92). Median TTF was similar at 9.24 months (ATA + TO...
|
PMID: 17971594
PDF is available here.
PDF is available here.
Fertility and Sterility (88)4 2007
Abstract
OBJECTIVE: To evaluate whether toremifene, a selective estrogen receptor modulator (SERM), has a beneficiary effect on all three main sperm parameters. DESIGN: Prospective interventional clinical study. SETTING: University hospital. PATIENT(S): One-hundred subfertile men with idiopathic oligozosperm...
|
PMID: 17412336
PDF is available here.
PDF is available here.
Journal of Urology (178)3 Pt 2 2007
Abstract
There are many agents that may decrease the risk of prostate cancer. It requires careful study of the agents in specific populations to determine whether risk is reduced, the magnitude of the risk reduction and the spectrum of side effects associated with the agent. Physicians caring for men enterin...
|
PMID: 17644117
PDF is available here.
PDF is available here.
Abstract
We compared the effects of atamestane (ATA) and toremifene (TOR) alone and in combination, with letrozole (LET) on bone, serum lipids and the uterus in ovariectomized (OVX) rats after 16 weeks of treatment. Compared to OVX controls lumbar vertebral and femoral BMD as well as mechanical strength and...
|
PMID: 17063268
PDF is available here.
PDF is available here.
Abstract
High-dose toremifene therapy (120 mg/day) is useful for the recurrence of receptor-positive breast cancer. However, some reports show that combination therapy of high-dose toremifene and chemotherapy exhibits additive effects. Twelve patients were given oral chemotherapy (capecitabine, 5'-DFUR+CPA,...
|
PMID: 17637560
PDF is available here.
PDF is available here.
Cancer Letters (251)2 2007
Abstract
We have reported important benefits and survival with an immunotherapy schedule in patients with endocrine-dependent breast cancer and distant metastases. Here clinical outcome is updated and its correlation with new immunological data is shown. In 32 evaluated breast cancer patients with endocrine-...
|
PMID: 17215077
PDF is available here.
PDF is available here.
Minerva stomatologica (56)4 2007
Abstract
Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes. Influencing factors are: gynecomasty, familiarity for male breast cancer, Jewish and African-American male population. F...
|
PMID: 17452960
PDF is available here.
PDF is available here.
Lancet Oncology (8)4 2007
Abstract
Abstract
The patient was a 36-year-old woman, who found a mass in her right breast around April 2002, visited a physician in June, and was referred to our department because of suspected right breast cancer. It was confirmed that the cancer had metastasized to the right axillary lymph nodes and the skin of t...
|
PMID: 17353638
PDF is available here.
PDF is available here.
Abstract
A 47-year-old woman was admitted to our hospital for advanced breast cancer with multiple liver metastases and liver dysfunction in January 2004. EC (EPI combined with CPA), weekly PTX, and AI were performed but were not effective for that tumor. Therefore, high-dose TOR was started. Liver dysfuncti...
|
PMID: 17353641
PDF is available here.
PDF is available here.
Abstract
We have characterized the DNA adducts produced by alpha-hydroxytoremifene and have compared the extent of hepatic DNA adduct formation in rats administered toremifene, alpha-hydroxytoremifene, or tamoxifen. alpha-Hydroxytoremifene was synthesized, further activated by sulfation, and then reacted wit...
|
PMID: 17261033
PDF is available here.
PDF is available here.
Current Medicinal Chemistry (14)11 2007
Abstract
Selective estrogen receptor modulators (SERMs), known previously as "antiestrogens", are a new category of therapeutic agents used for the prevention and treatment of diseases such as osteoporosis and breast cancer. SERMs act as ER-agonist in some tissues while acting as ER-antagonist in others base...
|
PMID: 17504144
PDF is available here.
PDF is available here.
Abstract
This study was performed to examine the effects of selective estrogen receptor modulators [tamoxifen (TAM) and toremifene (TOR)] and pure anti-estrogen, ICI-182780 (ICI, Faslodex) and soybean isoflavone, genistein (GE) on the expression of estrogen-stimulated c-fos/jun, ERalpha/beta and COX-1/2 in t...
|
PMID: 17479667
PDF is available here.
PDF is available here.
Abstract
The patient was a 76-year-old woman, who found a mass in her left breast around summer of 2003 but ignored it. She visited our hospital in April 2004 because of dyspnea and low-back pain. As there was a mass accompanied by partial ulceration all over the left precordium and bilateral pleural effusio...
|
PMID: 17220673
PDF is available here.
PDF is available here.
Abstract
Coronary artery disease (CAD) is the main contributor of mortality among postmenopausal women. Menopause-associated estrogen deficiency has both metabolic and vascular consequences that increase the risk for CAD. Hormone therapy (HT) has been reported to have a beneficial effect on metabolic and vas...
|
PMID: 17308162
PDF is available here.
PDF is available here.
Abstract
Lymph node status in the elderly breast cancer patient treated with hormonal therapy alone is a strong predictor of early distant recurrence....
|
PMID: 16920425
PDF is available here.
PDF is available here.
Journal of Urology (176)3 2006
Abstract
Toremifene decreased the incidence of prostate cancer by 1 year and had a tolerability profile comparable to that of placebo in a high risk population....
|
PMID: 16890670
PDF is available here.
PDF is available here.
Abstract
Hormone receptors and, specifically, estrogen receptors were described about four decades ago. For estrogens, there are two receptors, estrogen receptor alpha (ERalpha) and estrogen receptor beta (ERbeta). The two receptors are coded by different genes and their tissue expression varies across organ...
|
PMID: 17117297
PDF is available here.
PDF is available here.
Abstract
Adenomyosis has been reported in a number of different animal species, whereas endometriosis appears limited to humans and non-human primates. This suggests a different aetiology of the two conditions. Adenomyosis develops spontaneously in certain strains of laboratory mice. Its inci...
|
PMID: 16500151
PDF is available here.
PDF is available here.
Cancer Science (97)6 2006
Abstract
Effects of hepatocarcinogenic TAM and non-hepatocarcinogenic TOR on the formation of hepatic DNA adducts and on the gene expression of hepatic drug-metabolizing enzymes and DNA repair enzymes/proteins were comparatively examined in female Sprague-Dawley rats treated with TAM (20 or 40 mg/kg/day, i.g...
|
PMID: 16734724
PDF is available here.
PDF is available here.
Abstract
About 32 women were randomised to receive toremifene first and 30 to receive placebo first. Twenty-nine and 27 participants in the groups treated with toremifene first or placebo first completed the treatment, respectively. There were significant reductions in VAS scores in both groups after three t...
|
PMID: 16709215
PDF is available here.
PDF is available here.
Abstract
In this study, two selective estrogen receptor modulators (SERMs), tamoxifen (TAM) and toremifene (TOR) or two estrogens, ethinylestradiol (EE) and diethylstilbestrol (DES) were administered to newborn male and female Sprague-Dawley rats (days 1–5) to investigate the occurrence of developmental abn...
|
PMID: 16709447
PDF is available here.
PDF is available here.
Hepatology (43)4 2006
Abstract
We investigated the long-term development of these estrogen-induced foci of altered hepatocytes (FAH). We divided 451 Lewis rats into one main group (MG) and 11 (7 female, 4 male) control groups and observed them for up to 30 months. MG animals were ovariectomized and received ovarian transplants in...
|
PMID: 16557532
PDF is available here.
PDF is available here.
The Breast (15)2 2006
Abstract
We reviewed all preclinical and clinical safety data from 1978 to 2004 and comparative clinical safety data between October 1995 and the end of 2004. Secondary endometrial cancer incidence was lower with toremifene than with tamoxifen and was similar to that with raloxifene. It is speculated that to...
|
PMID: 16289904
PDF is available here.
PDF is available here.
Abstract
Deregulation of the estrogen axis in humans prompts a series of tissue-specific events. In the breast and prostate, alterations in estrogen signalling lead to genotypic and phenotypic molecular alterations that result in dysplastic cellular appearance, deregulated cell growth and carcinoma. In bone,...
|
PMID: 16503765
PDF is available here.
PDF is available here.
Abstract
Our results contrast to the previous observation detecting TAM-DNA adducts in several patients treated with TAM, indicating that TOR is less genotoxic to humans....
|
PMID: 16544947
PDF is available here.
PDF is available here.
Abstract
We have established novel MCF-7 cell line-derived in vitro models of anti-estrogen- and progestin-resistant and estrogen-independent breast cancer by long-term culture in the presence of toremifene and medroxyprogesterone acetate (MPA) and in the absence of estradiol, respectively. Using cell growth...
|
PMID: 16152593
PDF is available here.
PDF is available here.
Abstract
Ocular toxicity was reported in 538 of 4948 (10.9%) patients during adjuvant treatment, mainly during chemotherapy. Forty-five of 4948 (0.9%) patients had ocular toxicity during hormone therapy alone, but only 30 (0.6%) patients had ocular toxicity reported either without receiving any chemotherapy...
|
PMID: 16369994
PDF is available here.
PDF is available here.
The Breast (15)1 2006
Abstract
The prognostic and predictive relevance of p53 immunoreactivity is used here as a tentative approach for defining more accurately the benefit of adjuvant hormonal therapy in postmenopausal node-positive breast cancer patients. Ninety-seven postmenopausal patients with axillary lymph node metastasis...
|
PMID: 16005229
PDF is available here.
PDF is available here.
Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC (28)1 2006
Abstract
To review the current management of women with breast pain.
The effect of various treatment modes and health practices, including medications, was considered for the management of both cyclical and noncyclical breast pain.
Effective and timely manageme...
|
PMID: 16533457
PDF is available here.
PDF is available here.
Archives of Surgery (141)1 2006
Abstract
Toremifen effectively relieves moderate and severe cyclical mastalgia and tends to exert a positive therapeutic effect on noncyclical mastalgia. In addition, toremifen therapy does not increase the incidence of intolerable adverse event. Therefore, it is a feasible therapy for mastalgia, especially...
|
PMID: 16415410
PDF is available here.
PDF is available here.
Abstract
We describe a microarray experiment using the MCF-7 breast cancer cell line in two different experimental conditions for which the same number of independent pools as the number of individual samples was hybridized on Affymetrix GeneChips. Unexpectedly, when using individual samples, the number of p...
|
PMID: 16847808
PDF is available here.
PDF is available here.
Abstract
We studied the mechanisms by which Tam exerts rapid effects on breast cancer cell viability. In serum-free medium 5-7 microM Tam induced death of MCF-7 and MDA-MB-231 cells in a time-dependent manner in less than 60 min. This was associated with release of mitochondrial cytochrome c, a decrease of m...
|
PMID: 16215679
PDF is available here.
PDF is available here.
Abstract
We conclude that: (a) assessment of toremifene 60 mg/day in chemoprevention will require further clinical trials; (b) toremifene 60 mg/day has no substantive negative effects on BMD in pre- or postmenopausal women and may exert a minor favourable influence (in particular, the effects of toremifene 6...
|
PMID: 16172794
PDF is available here.
PDF is available here.
Abstract
We tried to study retrospectively the efficacy and the safety of high-dose TOR treatment for patients with MBC in our hospital. Ten patients received TOR 120 mg daily. Most of the patients were treated with one or more endocrine agents before high-dose TOR. Objective response and clinical benefits w...
|
PMID: 16227740
PDF is available here.
PDF is available here.
Fertility and Sterility (84)2 2005
Abstract
Our case demonstrates that toremifene is a safe and effective therapy that can be used for the stabilization and regression of desmoid tumors. An antiestrogen should be considered as adjuvant therapy after surgery and as a first-line treatment with disease recurrence. Discontinuation of antiestrogen...
|
PMID: 16086575
PDF is available here.
PDF is available here.
Neurosurgery (56)6 2005
Abstract
OBJECTIVE AND IMPORTANCE: A case of an unusual intracranial solitary fibrous tumor with features of high vascularity and resultant difficulty at resection is presented. The use of surgery, radiotherapy, and toremifene has been successful with no recurrence after 18 months. CLINICAL PRESENTATION: A 3...
|
PMID: 15918957
PDF is available here.
PDF is available here.
Abstract
We started an exploratory clinical trial based on the association of these immunostimulating cytokines with antiestrogens for first line salvage therapy of hormone dependent breast cancer with distant metastases. Twenty-six consecutive breast cancer patients with distant metastases, 23 of which had...
|
PMID: 15913946
PDF is available here.
PDF is available here.